Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing
Authors:
- J MassieJMJ Massie
- L CurnowLCL Curnow
- N TzanakosNTN Tzanakos
- I FrancisIFI Francis
- C F RobertsonCRC F Robertson
- 1 March 2006
- journal article
- research article
- Published by BMJ in Archives of Disease in Childhood
- Vol. 91 (3) , 222-225
Abstract
Aims: To investigate the immunoreactive trypsinogen (IRT) values above the usual 99th centile laboratory cut-off and determine the value of offering further testing to those infants with a markedly elevated IRT but no cystic fibrosis transmembrane regulator (CFTR) gene mutation identified by the screening programme. Methods: All babies born in Victoria, Australia, between 1991 and 2003, were screened by IRT followed by CF gene mutation analysis. Results: Of the 806 520 babies born, 9268 with the highest IRT levels had CFTR mutation analysis. There were 123 ΔF508 homozygotes and 703 heterozygotes (86 with CF, 617 carriers). A total of 8442 babies had no CFTR gene mutation, of whom 18 (0.21%) had CF. The total number of CF babies with IRT greater than the laboratory cut-off was 227 (2.4%). The IRT results of the CF patients were distributed normally, with the majority above the laboratory cut-off of newborn IRT results. There was no evidence of an excess of babies with CF in the very highest levels of IRT above the 99th centile. Conclusions: Only a small proportion of babies with a neonatal IRT >99th centile have CF. Additional CF testing for infants with an elevated IRT but no CFTR gene mutation has an extremely low yield, no matter how high the IRT result.Keywords
This publication has 8 references indexed in Scilit:
- Newborn screening for cystic fibrosis in Victoria: 10 years' experience (1989‐1998)Medical Journal of Australia, 2000
- Newborn Screening for Cystic Fibrosis in Wisconsin: Comparison of Biochemical and Molecular MethodsPediatrics, 1997
- The impact of newborn screening on cystic fibrosis testing in Victoria, Australia.Journal of Medical Genetics, 1995
- Cystic fibrosis screening in neonates — measurement of immunoreactive trypsin and direct genotype analysis for ΔF508 mutationEuropean Journal of Pediatrics, 1994
- Neonatal screening for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis: four years' experienceBMJ, 1994
- Immunoreactive trypsinogen screening for cystic fibrosis: Characterization of infants with a false‐positive screening testPediatric Pulmonology, 1989
- Screening, early neonatal diagnosis and prenatal diagnosis.1986
- DRIED-BLOOD SPOT SCREENING FOR CYSTIC FIBROSIS IN THE NEWBORNThe Lancet, 1979